Get the Stockscreener App
12.98
5.96%
0.73
Pre-market:
13.61
0.63
+4.85%
Oruka Therapeutics Inc stock is traded at $12.98, with a volume of 695.75K.
It is up +5.96% in the last 24 hours and down -36.09% over the past month.
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
See More
Previous Close:
$12.25
Open:
$12.5
24h Volume:
695.75K
Relative Volume:
2.67
Market Cap:
$454.28M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.42%
1M Performance:
-36.09%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$12.24
$13.62
1-Week Range:
$12.23
$14.85
52-Week Range:
$12.23
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
12.98 | 454.28M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Buy” from Analysts - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year Low – Time to Sell? - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month LowHere's What Happened - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 7.8%Should You Sell? - MarketBeat
Geode Capital Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year LowWhat's Next? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 8%What's Next? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) versus Myriad Genetics (NASDAQ:MYGN) Head to Head Comparison - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week LowShould You Sell? - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $43.17 Consensus Target Price from Analysts - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.2%Time to Sell? - MarketBeat
Critical Contrast: BG Medicine (OTCMKTS:BGMD) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Franklin Resources Inc. Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
H.C. Wainwright bullish on Oruka stock after early clinical success for ORKA-001 - Investing.com Canada
Oruka Therapeutics' (ORKA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 - Yahoo Finance
Oruka Therapeutics enters exclusive licensing deal with Paragon - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) Shares Down 4.7%Should You Sell? - MarketBeat
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody - The Manila Times
Oruka Therapeutics Announces First Participants Dosed in - GlobeNewswire
Oruka Therapeutics Launches Phase 1 Trial of Revolutionary Long-Acting Psoriasis Treatment ORKA-001 - StockTitan
Wellington Management Group LLP Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Wellington Management Group LLP Takes $2.01 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Oruka Therapeutics to Join Prestigious Nasdaq Biotechnology Index in Major Milestone - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) Sees Large Volume IncreaseShould You Buy? - MarketBeat
The Manufacturers Life Insurance Company Acquires New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
The Manufacturers Life Insurance Company Invests $1.04 Million in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% - Yahoo Finance
Frazier Life Sciences Management L.P. Purchases New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Janus Henderson Group PLC Acquires Shares of 236,116 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Point72 Asset Management L.P. Acquires Shares of 482,330 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
RTW Investments LP Takes $45.36 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Redmile Group LLC Acquires Shares of 411,728 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Fmr LLC Buys Shares of 4,682,300 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics: Strong Q3 and Strategic Advances - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Buy” by Brokerages - Defense World
Braidwell LP Acquires New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Up 7.4%Here's Why - MarketBeat
Great Point Partners LLC Takes $12.61 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for ORKA - MarketBeat
Oruka stock stays Buy-rated as H.C. Wainwright emphasizes annual dosing potential for ORKA-001 - Investing.com UK
ARCA BIOPHARMA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Oruka Therapeutics (NASDAQ:ORKA) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Fairmount Funds Management LLC's Strategic Acquisition in Oruka Therapeutics Inc - GuruFocus.com
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference - The Manila Times
Oruka Therapeutics to Present at Piper Sandler Healthcare Conference | Psoriasis Drug Developer | ORKA Stock News - StockTitan
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference - GlobeNewswire
Oruka Therapeutics gains approval for preferred stock conversion - Investing.com
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):